EIF2S3

Across TCGA pan-cancer cohorts, EIF2S3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EIF2S3 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EIF2S3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EIF2S3 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

CCRCC, GBM, and HNSC are the cancer types where EIF2S3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.630	0.858	.001	14	view →
GBM	DFS	Median	All	0.437	0.304	.021	6	view →
HNSC	DFS	Median	All	0.721	0.559	.028	4	view →
LUAD	OS	Quartile	II,III,IV	0.224	0.839	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EIF2S3–CCRCC (DFS)

Open the CCRCC breakdown →